Plus Therapeutics to Execute 1-for-25 Reverse Split, Cuts Shares to 6.86 Million
Plus Therapeutics will implement a 1-for-25 reverse stock split effective April 2, 2026 at 12:01 a.m. ET, reducing its outstanding shares from approximately 171.6 million to about 6.86 million. The move aims to raise its per-share price above the $1.00 minimum requirement for continued Nasdaq Capital Market listing.
1. Reverse Stock Split Details
Plus Therapeutics’ Board approved a 1-for-25 reverse stock split effective at 12:01 a.m. ET on April 2, 2026. Every 25 existing common shares will convert into one share, reducing outstanding shares from 171,550,698 to approximately 6,862,027, and the company will trade under its existing symbol with a new CUSIP.
2. Purpose and Shareholder Impact
The reverse split is designed to lift the per-share price above the $1.00 minimum bid requirement for continued listing on the Nasdaq Capital Market. Fractional shares will be settled in cash, outstanding equity awards and warrants will be adjusted, and certificate holders will receive exchange instructions from the transfer agent while brokerage accounts will reflect changes automatically.